QURE - 5 Best Mid-Cap Biotech Acquisition Targets
Q4 2019 has been the best quarter ([[IBB]] up 22.5% [[XBI]] up 26.7%) for biotech investors since Q1 2015, which was the top of 2014-2015 rally. This 20+% rally is largely attributed to Fed's overall easing stance, increased mergers & acquisitions, positive regulatory backdrop, solid trial results and better-than-expected corporate earnings. 2019 deal activity has increased significantly, and large Biopharma companies are actively conducting mergers and acquisitions in order to deliver higher long-term return for their investors.
Based on data from Chimera Research Group (Biotech M&A - 2019 Deals), there were 28 biotech